Leaving Community
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Blog
dkNET community events and announcements in March, 2022
Dear dkNET Community,
dkNET provides updates on activities of interest to the NIDDK-supported community. You could keep up to date on these activities through our Twitter feed @dkNET_info, through our Community Calendar, or through dkNET e-mail list. If you have an event or funding opportunities you'd like to advertise, please contact us info_at_dknet.org.
dkNET News
Join dkNET Upcoming Webinars: (1) dkNET New Investigator Pilot Program in Bioinformatics Awardee Webinar “Uncovering Novel Mediators and Mechanisms of Leptin Action,” presented by Dr. Alan Rupp on February 25, 2022, 11 am-12 pm PT. Learn more:https://dknet.org/about/blog/2407. (2) dkNET webinar “The Pediatric Obesity Metabolome And Microbiome Study (POMMS),” is being presented by Drs. John F. Rawls and Jessica R. McCann on March 11, 2022, 11 am-12 pm PT. Don’t miss out on this opportunity to learn about newly derived characteristics of adolescent #obesity - https://dknet.org/about/blog/2411
Recordings and Slides are Now Available for the dkNET webinar (1) “Pancreatlas™: Mapping The Human Pancreas In Health And Disease,” presented by Drs. Marcela Brissova, Jean-Philippe Cartailler, and Dr. Diane Saunders on January 28, 2022: Recording; Slides. (2) "The Stimulating Peripheral Activity To Relieve Conditions (SPARC): Advancing Bioelectronic Medicine Through Open Science", presented by Dr. Maryann Martone on February 11, 2022: Recording; Slides.
Congratulations to the dkNET Summer of Data Student Aditya More on publishing a paper studying the role of adipocyte PU.1 in age-associated metabolic syndrome. Aditya joined the 2020 dkNET summer program and she used the dkNET Hypothesis Center - Signaling Pathways Project (SPP) tool in her paper!
The 2022 dkNET Summer of Data Student Program is a 6-week opportunity for students (highschool to Masters/ PhD graduate) to learn rigor and reproducibility practices, FAIR data management, & dkNET resources for experimentation! dkNET is accepting applications now! This program requires that students are involved with an NIDDK-related research lab during summer 2022. dkNET offers limited scholarships to student applicants. Application due date: April 18, 2022.
Funding Opportunity: dkNET New Investigator Pilot Program in Bioinformatics
Are you an early-stage/new investigator who wants to develop and apply computational methods to support diabetes, endocrinology or metabolic disease research? Submit your Application Deadline: February 28, 2022 (LOI is not required).
- New Resources added to dkNET
- CellChat (RRID:SCR_021946) is a software R toolkit for inference, visualization and analysis of cell-cell communication from single cell data. It quantitatively infers and analyzes intercellular communication networks from single-cell RNA-sequencing data. It predicts major signaling inputs and outputs for cells and how those cells and signals coordinate for functions using network analysis and pattern recognition approaches. It classifies signaling pathways and delineates conserved and context specific pathways across different datasets.
- Dimensions (RRID:SCR_021977) is a database that aggregates, harmonizes and links records of various publication types from diverse sources, including Crossref and PubMed Central using automated routines and artificial intelligence technologies. It contains publications, ranging from articles published in scholarly journals, books and book chapters, to preprints and conference proceedings. All publications are contextualized with linked data sets, funding, publications, patents, clinical trials, and policy documents. You can also view associated categories, funders, institutions, and researcher profiles.
- ExoCarta (RRID:SCR_021960) is a manually curated database of exosomal proteins, RNA and lipids. It contains a web-based compendium of exosomal cargo. It is a database that catalogs information from both published and unpublished exosomal studies. Mode of exosomal purification and characterization, biophysical and molecular properties are listed.
- miRandola (RRID:SCR_021961) It is a manually curated database containing information on extracellular and circulating non-coding RNAs.You can search for RNAs typing in text area molecules of interest or you can browse the database. It was initially published in 2012, foreseeing the relevance of ncRNAs as non-invasive biomarkers. miRandola 2017 is an effort to update and collect accumulating information on extracellular ncRNAs that is spread across scientific publications and different databases with implemented new web interfaces.
Events in March 2022
Mar. 03, 2022
Explore the Lipidome Part I
Avanti is excited to announce a 2022 webinar series titled "Explore the Lipidome". This will be a three part series with invited speakers who are prominent members of the lipidomic research community. In this three part series, distinguished speakers will discuss the importance of standardization in lipidomics, as well as their current research in the field. This is something you don't want to miss! Get ready to explore the lipidome with this Avanti webinar series.
Date: Thursday, March 03, 2022 at 09:00-10:00AM CST (07:00-08:00AM PST)
Speaker(s): Maria Fedorova
Mar. 04, 2022
DRTC Friday Seminar Series
DRTC Friday Seminar Series: "TBD" virtual webinar on Friday, March 4, 2022 at 12:00pm CST (10:00am PST)
Speaker: Seth Bordenstein, PhD, Vanderbilt University
More Information: https://www.vumc.org/vdrc/drtc-friday-seminar-series
Mar. 04, 2022
Satija Lab Single Cell Genomics Day: A (Virtual) Practical Workshop
Recent developments in molecular biology, microfluidics, and computational biology have transformed the field of single cell genomics, and have widespread biological applications. However, the breathtaking pace of technology development has given rise to a multitude of molecular protocols, commercial systems, and computational challenges.
The Satija Lab is excited to host the sixth annual Single Cell Genomics Day on Friday, March 4, 2022. This workshop will begin with an overview of exciting developments in the field over the past year, followed by in-depth presentations on exciting methods and techniques. Our goal is to empower you to utilize single cell genomics in your work. The workshop is free and open to beginners and experts alike.
This workshop takes place on Friday March 4, 2022 10:00 AM to 5:00 PM EDT - no registration required!
More Information: https://satijalab.org/scgd22/
Mar. 07, 2022
Abstract Submission Due: NLM Curation at Scale Workshop
The NLM Curation at Scale workshop – held virtually on Zoom from March 28 to March 30, 2022 – will bring together biocurators, developers of automated curation systems, and other stakeholders. The workshop offers an opportunity to learn about the current status of biomedical data curation, share research and challenges, and discuss the implementation of advanced computational techniques in scientific data curation. In addition to curation, the workshop will provide an opportunity to discuss key related aspects such as data standards and sharing.
Meeting dates: March 28 to March 30, 2022 (virtual)
Poster abstract submission deadline: March 7, 2022
Registration deadline: March 21, 2022
More Information: https://www.nlm.nih.gov/curationworkshop2022/index.html
Mar. 10, 2022
the(sugar)science The State of Science II: "Interdisciplinary Approaches"
the(sugar)science is hosting The State of Science 2022 T1D Series: "Interdisciplinary Approaches: Placenta as an immune privileged space, are there implications for islet implantation and more?"
The State of Science II is holding this virtual discussion on Thursday, March 10, 2022 at 8-9 am PST // 11-12 noon EST // 4-5 pm GMT
Anchors: Carmella Evans-Molina MD PhD (IU), Jessica Weaver PhD (ASU), Qizhi Tang PhD (UCSF), Allison Bayer PhD (DRI Miami)
More Information: https://thesugarscience.org/state-of-the-science-2022/
Mar. 11, 2022
DRTC Friday Seminar Series: "TBD"
DRTC Friday Seminar Series: "TBD" virtual webinar on Friday, March 11, 2022 at 12:00pm CST (10:00am PST)
Speaker: Bethany Cummings, PhD, UC Davis
More Information: https://www.vumc.org/vdrc/drtc-friday-seminar-series
Mar. 11, 2022
dkNET Webinar: Pediatric Obesity Microbiome And Metabolism Study (POMMS)
Join dkNET Webinar on Friday, March 11, 2022, 11am-12pm PST
Presenter: John F. Rawls, PhD (Professor) and Jessica R. McCann(Senior Research Associate), Departments of Molecular Genetics & Microbiology, Duke Microbiome Center, Duke University School of Medicine
Pediatric obesity strongly predicts adult obesity as well as metabolic and cardiovascular disease. However recommended interventions result in a heterogeneous response and underlying predictive factors for treatment success remain unknown. We designed the POMMS study (https://sites.duke.edu/pomms/) to characterize the microbiome and metabolome in adolescents with obesity (OB) at baseline when compared to an age-matched healthy weight control group (HWC), and in response to weight loss intervention. We enrolled a racially and ethnically diverse group of 223 adolescents aged 10-18 years with Body Mass Index (BMI) ? 95th percentile, along with 71 HWC participants. We collected clinical data, fasting serum, and fecal samples at repeated intervals over a 6 month intervention. Here we present clinical data, targeted serum metabolite measurements, fecal 16S rRNA gene amplicon sequencing as well as fecal microbiome shotgun sequencing of samples from adolescents both at baseline and study completion. We found that clinical correlates such as insulin levels at baseline were associated with intervention outcome. While adolescents with OB had predictably higher clinical lab values when compared to HWC counterparts, we found evidence of a metabolite signature that appears to be unique to adolescents with OB and unlike adults with OB. Several targeted metabolites and specific microbial taxa at baseline were significantly associated with OB versus HWC status, or with changes in BMI or insulin resistance scores following the intervention. Preliminary analysis of microbiome shotgun sequencing suggested that distinct metabolic and enzymatic pathways encoded by the microbiome were associated with OB v HWC status at baseline. Fecal microbiome transplant studies using gnotobiotic mice have previously established that microbiomes from adult donors with OB are sufficient to promote weight gain, adiposity, and associated metabolic signatures. However, it remained unknown whether microbiome from adolescents with OB has similar causal roles. We colonized germ-free mice with fecal slurries from baseline and 6-month patient samples. Physiologic and metabolic outcomes were compared with those from mice colonized with age matched HWC fecal slurries. While metabolomic and longitudinal sampling results from these FMT studies are pending, we found that starting weight of the recipient mice had the strongest association with weight gain, followed by OB versus HWC status of the donor. In conclusion, we identify a unique metabolomic and microbiome signature of obesity in adolescents, features of which could be used to predict intervention outcome.
More Information: https://dknet.org/about/webinar
Mar. 15, 2022
LIPIDMAPS Webinar: "Lipidomics to Find Bioactive Lipids"
Alan Saghatelian attended UCLA from 1993-1997 and earned a B.S. degree in chemistry and then obtained his Ph.D. in chemistry from the Scripps Research Institute in 2002. Dr. Saghatelian remained at Scripps and worked with Professor Benjamin Cravatt for his postdoctoral research. Dr. Saghatelian developed lipidomics methods to profile cells and tissues. In 2006, Dr. Saghatelian began his independent career in the Department of Chemistry and Chemical Biology at Harvard University. His research program at Harvard identified novel human peptides and small proteins (microproteins) encoded by small open reading frames (smORFs) and the discovery of structurally novel bioactive lipids. As his research became more focused on biology, Dr. Saghatelian decided to move to the Salk Institute to pursue emerging biological questions. At Salk, the Saghatelian lab has identified the enzymes responsible for novel lipid regulation and found thousands of new microproteins. Dr. Saghatelian is a recipient of the NIH New Innovator Award, a Searle Scholar Awardee, and a Sloan Foundation and AAAS Fellow.
Presented by Professor Alan Saghatelian
LIPIDMAPS Webinar "Lipidomics to Find Bioactive Lipids" will be held virtually on 15th March 2022 at 5pm GMT | 10am PDT | 1pm EDT
Register at the link below
More Information: https://www.lipidmaps.org/resources/webinars/20
Mar. 18, 2022
DRTC Friday Seminar Series
DRTC Friday Seminar Series: "TBD" virtual webinar on Friday, March 18, 2022 at 12:00pm CST (10:00am PST)
Speaker: Beiyan Zhou, PhD, UCONN Health Center
More Information: https://www.vumc.org/vdrc/drtc-friday-seminar-series
Mar. 20-23, 2022
Keystone Symposia: Gut-Brain Axis
The gut-brain axis encompasses bidirectional communication between the gastrointestinal tract and the central nervous system (CNS). This is mediated via the autonomic nervous system, including the vagus nerve and enteric nervous system (ENS), and endocrine, immune, and metabolic pathways. These systems coordinate physiology and behavior in health and disease. The underlying mechanisms and pathways are now being elucidated in this emerging area of scientific interest. Understanding the gut-brain axis augments neurobiological mechanisms and provides opportunities to treat CNS disorders from the periphery as well as metabolic and immunologic diseases. This meeting will bring together basic and applied scientists from across academia and industry to advance our understanding of gut-brain signaling.
Conference Dates: March 20-23, 2022
Scholarship Deadline: November 30 2021
Abstract Deadline: December 7 2021
More Information: https://www.keystonesymposia.org/conferences/conference-listing/meeting?eventid=6839
Location: Fairmont Banff Springs, 405 Spray Ave, Banff, AB T1L 1J4, Cana
Mar. 21, 2022
Registration Due: NLM Curation at Scale Workshop
The NLM Curation at Scale workshop – held virtually on Zoom from March 28 to March 30, 2022 – will bring together biocurators, developers of automated curation systems, and other stakeholders. The workshop offers an opportunity to learn about the current status of biomedical data curation, share research and challenges, and discuss the implementation of advanced computational techniques in scientific data curation. In addition to curation, the workshop will provide an opportunity to discuss key related aspects such as data standards and sharing.
Meeting dates: March 28 to March 30, 2022 (virtual)
Poster abstract submission deadline: March 7, 2022
Registration deadline: March 21, 2022
More Information: https://www.nlm.nih.gov/curationworkshop2022/index.html
Mar. 24, 2022
the(sugar)science The State of Science II: "Integrating Approaches to T1D cures"
the(sugar)science is hosting The State of Science 2022 T1D Series: "Integrating Approaches to T1D cures: creating a roadmap, or a “Diabetosome” to connect to interdisciplinary research. Connecting disparate disciplines that add value to T1D research."
The State of Science II is holding this virtual discussion on Thursday, March 24, 2022 at 8-9 am PST // 11-12 noon EST // 4-5 pm GMT
Anchors: Danielle Dean PhD (VUMC), Rodica Pop-Busie MD (UMICH), Noel Burtt PhD (MIT/Broad), Cate Speake PhD (BRI), Carmella Evans-Molina MD PhD (IU), Vira Kravets PhD (CU/Barbara Davis)
More Information: https://thesugarscience.org/state-of-the-science-2022/
Mar. 25, 2022
Registration Deadline: Intestinal Stem Cell - Niche Interactions in Health and Disease Conference
The past ten years have seen an explosion of information regarding intestinal stem cells (ISCs), due to an improved ability to identify ISCs, follow their fates, and manipulate ISCs in vitro. The next frontier in the ISC field is understanding the role that dysregulated ISC behavior plays in the etiology of disease, and conversely, the impact of intestinal disease on proper ISC function. This meeting will bring together a diverse group of investigators to discuss topics such as how the environment of the small intestine and colon impacts ISC behavior in healthy and diseased states, how ISC behavior and the niche differ along the proximal-distal axis of the intestine, and the strengths of various models for investigating the relationship between ISCs, the niche, and the onset and propagation of disease states.
Meeting dates: 22 May 2022 - 25 May 2022 at Cancun, MX
Talk Submission Deadline: February 28, 2022
Poster Submission Deadline: March 25, 2022
Registration Deadline Deadline: March 25, 2022
More Information: https://www.fusion-conferences.com/conference/138
Mar. 25, 2022
Poster Submission Deadline: Intestinal Stem Cell - Niche Interactions in Health and Disease Conference
The past ten years have seen an explosion of information regarding intestinal stem cells (ISCs), due to an improved ability to identify ISCs, follow their fates, and manipulate ISCs in vitro. The next frontier in the ISC field is understanding the role that dysregulated ISC behavior plays in the etiology of disease, and conversely, the impact of intestinal disease on proper ISC function. This meeting will bring together a diverse group of investigators to discuss topics such as how the environment of the small intestine and colon impacts ISC behavior in healthy and diseased states, how ISC behavior and the niche differ along the proximal-distal axis of the intestine, and the strengths of various models for investigating the relationship between ISCs, the niche, and the onset and propagation of disease states.
Meeting dates: 22 May 2022 - 25 May 2022 at Cancun, MX
Talk Submission Deadline: February 28, 2022
Poster Submission Deadline: March 25, 2022
Registration Deadline Deadline: March 25, 2022
More Information: https://www.fusion-conferences.com/conference/138
Mar. 28, 2022
Registration Deadline: NIDDK NMRI Annual Meeting
The success of the NMRI, a network that is “owned” by its members and supported by the NIDDK, begins with the dedication of senior investigators who mentor and serve as role models for junior investigators. The participation of active members and the recruitment of new members is a primary reason for the Network’s success in the past and the reason for confidence that it will continue to grow in the future.
Registration Deadline: March 28, 2022
Meeting Dates: April 20-22, 2022
More Information: https://www.niddk.nih.gov/news/meetings-workshops/2022/nmri-annual-meeting-2022
Mar. 28-30, 2022
NLM Curation at Scale Workshop
The NLM Curation at Scale workshop – held virtually on Zoom from March 28 to March 30, 2022 – will bring together biocurators, developers of automated curation systems, and other stakeholders. The workshop offers an opportunity to learn about the current status of biomedical data curation, share research and challenges, and discuss the implementation of advanced computational techniques in scientific data curation. In addition to curation, the workshop will provide an opportunity to discuss key related aspects such as data standards and sharing.
Meeting dates: March 28 to March 30, 2022 (virtual)
Poster abstract submission deadline: March 7, 2022
Registration deadline: March 21, 2022
More Information: https://www.nlm.nih.gov/curationworkshop2022/index.html
Mar. 30, 2022
Earlybird Registration Deadline: Digestive Disease Week 2022
DDW 2022 will be taking place May 21-24, 2022, in San Diego, California and virtually. Join us in 2022 to discover the latest research, present your own and expand your knowledge. Whether you’re searching for insights, feedback or collaboration, you’ll find what you need to advance your goals at DDW 2022.
Thursday, Dec. 2, 2021: Abstract submission closes
March 30, 2022: Early bird registration deadline
Saturday, May 21–Tuesday, May 24, 2022: DDW 2022 takes place
More Information: https://ddw.org/attendee-planning/ddw-2022/
Mar. 30-Apr. 01, 2022
NIDDK BPH and Male LUTS: Intersection between Pathology and Disease
Benign prostatic hyperplasia (BPH) affects 50% of men over age 50. Ninety percent of men over age 80 become affected. Often men with BPH present with lower urinary tract symptoms (LUTS) and first-line treatment of such symptoms include medical management with 5a-reductase inhibitors to reduce prostate size and a -blockers to relax the urinary sphincter. Surgical therapies to resect the prostate can also be effective. However, many men do not find symptom relief from these prostate-targeted treatments and prostate size is often not correlated with severity of urinary symptoms. This raises the question as to whether male LUTS and BPH are syndromic or whether we should re-examine male LUTS within the framework of separating prostate pathology from bladder pathology. Over the last several years, new insights have emerged regarding the etiology of BPH, as well as the etiology of bladder dysfunction. There have also been significant advances in our understanding of the biology of aging, primarily from model systems. Given these advances, it is an opportune time to incorporate these data into a new understanding of BPH etiology and how prostate pathology relates to male LUTS.
Registration Deadline: March 24, 2022
Meeting: March 31 - April 1, 2022
More Information: https://www.niddk.nih.gov/news/meetings-workshops/2022/male-luts-prostate-workshop
Location: Bethesda, MD, USA
Funding Opportunities Information and Deadlines in March 2022
Mar. 01, 2022
NIDDK Funding Opportunity Letter of Intent Due: Elucidating the heterogeneity of impaired awareness of hypoglycemia in Type 1 Diabetes (T1D) - Biostatistics Research Center (U01 Clinical Trial Not Allowed)
This FOA invites applications for a Biostatistics Research Center (BRC) to participate in a clinical consortium to determine the factors that contribute to the heterogeneity in the restoration of impaired awareness of hypoglycemia (IAH) and improved counter-regulatory responses in adult individuals with Type 1 Diabetes (T1D) and impaired awareness of hypoglycemia (IAH). A separate FOA (RFA-DK-21-020) invites Clinical Centers to: 1) determine if the most up-to-date diabetes technology to optimize HbA1c while minimizing hypoglycemia can restore awareness of hypoglycemia and improve counter-regulatory responses in individuals with T1D and IAH; 2) identify the magnitude and duration of time in range (TIR), time spent in hypoglycemia or other CGM metrics that are associated with restoration of awareness of hypoglycemia; and 3) determine the association of current or newly developed self-reported measures of IAH with counter-regulatory responses to elucidate the heterogeneity in restoration of hypoglycemia awareness.
Letter of Intent Deadline: March 01, 2022
Application Deadline: March 31, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-036.html
Mar. 01, 2022
NIDDK Funding Opportunity Letter of Intent Due: Elucidating the heterogeneity of impaired awareness of hypoglycemia in Type 1 Diabetes (T1D) Clinical Centers (U01 Clinical Trial Required)
The purpose of this FOA is to establish a clinical consortium to determine the factors that contribute to the heterogeneity in the restoration of impaired awareness of hypoglycemia (IAH) and improved counter-regulatory responses in adult individuals with Type 1 Diabetes (T1D). Individuals with IAH are often excluded from clinical trials and this omission contributes greatly to a lack of knowledge regarding the clinical characteristics which determine or predict an individual’s ability to restore hypoglycemic awareness. New technologies such as continuous glucose monitors (CGM) and closed loop systems (i.e. artificial pancreas) have been shown to reduce hypoglycemic events. However, despite a reduction in hypoglycemic events, restoration of hypoglycemia awareness does not occur in all individuals and the effects on improving the counter-regulatory responses are not known.
Letter of Intent Deadline: March 01, 2022
Application Deadline: March 31, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-020.html
Mar. 01, 2022
HIRN Funding Opportunity Letter of Intent Due: Catalyst Award
The Human Islet Research Network (HIRN) announces a new funding initiative to support investigators developing bold, innovative, and challenging projects that will catalyze the field and provide important advances in topics of interest to the network. To be considered “catalyzing”, the proposed research must address significant and currently intractable problems by employing approaches or ideas that are currently outside the mainstream of contemporary research. The program is not intended to expand a current research program's funding in the area of the proposed project, but instead must reflect a fundamental new insight or understanding that will revolutionize the field. Catalyzing advances may emanate from the application of exceptionally innovative approaches and/or from testing radically unconventional hypotheses.
Letter of Intent Deadline: March 1, 2022
Application Deadline: May 2, 2022
More Information: https://dknet.org/about/dknetnews/2377
Mar. 01, 2022
IIDP Funding Opportunity Application Due: Islet Award Initiative
The IIDP Islet Award Initiative is intended to advance research in human islet biology by facilitating the ability of researchers to access human islets for high impact and novel research studies. The number of IIDP Islet Awards funded under this initiative will be determined in any single year based on available resources but will average 3-4 awards per submission date.
Application Deadline: March 1, 2022
More Information: https://iidp.coh.org/Investigators/Islet-Award-Initiative
Mar. 02, 2022
NIH Funding Opportunity Application Due: HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices is not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery.
Letter of Intent Deadline: 30 days prior to the application due date.
Application Deadline: March 02, 2022, June 02, 2022, October 04, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-ns-22-034.html
Mar. 03, 2022
NIDDK Funding Opportunity Application Due: Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes – Clinical Centers (U01 Clinical Trial Not Allowed)
The purpose of this FOA is to create a clinical consortium to recruit a cohort of early pubertal youth at risk for developing type 2 diabetes and study them through puberty. The ultimate goal of this undertaking will be to 1) develop more precise prediction of which individuals are truly at risk for developing youth-onset T2D and identify determinants of progression from prediabetes to T2D so that, ultimately, targeted prevention approaches can be developed and tested; and 2) increase understanding of the physiologic drivers of youth-onset T2D to guide development of more effective strategies to achieve glycemic control and preserve beta cell function.
Letter of Intent Deadline: February 03, 2022
Application Deadline: March 03, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-002.html
Mar. 03, 2022
NIDDK Funding Opportunity Application Due: High-Resolution Exploration of the Human Islet Tissue Environment [HIRN Human Pancreas Analysis Consortium (HPAC)] (U01 - Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites cooperative agreement applications that will contribute to a higher resolution understanding of the organization of the human pancreatic tissue environment by describing the composition and function of important components of the pancreatic islet and peri-islet tissue architecture, the cell-cell relationships and means of communications used by cell types and cell subtypes within the pancreatic tissue ecosystem, and the contribution of adjacent tissues to islet cell function and dysfunction. Successful projects will integrate the Human Pancreas Analysis Consortium (HPAC) that is part of the Human Islet Research Network or HIRN (https://hirnetwork.org/). HIRN's overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This FOA will only support studies with a primary focus on increasing our understanding of human tissue structure and function, and human disease biology, as opposed to exploring the biology specific to any animal models.
Letter of Intent Deadline: February 3, 2022
Application Deadline: March 3, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-017.html
Mar. 03, 2022
NIDDK Funding Opportunity Application Due: Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes – Biostatistics Research Center (U01 Clinical Trial Not Allowed)
This FOA invites applications for a Biostatistics Research Center to participate in a clinical consortium to better understand youth-onset type 2 diabetes. A separate FOA (RFA-DK-21-002) invites Clinical Centers to recruit a cohort of early pubertal youth at risk for developing type 2 diabetes and study them through puberty. The ultimate goals of this consortium will be to 1) develop more precise prediction of which individuals are truly at risk for developing youth-onset T2D and identify determinants of progression from prediabetes to T2D so that, ultimately, targeted prevention approaches can be developed and tested; and 2) increase understanding of the physiologic drivers of youth-onset T2D to guide development of more effective strategies to achieve glycemic control and preserve beta cell function.
Letter of Intent Deadline: February 03, 2022
Application Deadline: March 03, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-003.html
Mar. 05, 2022
NIH Funding Opportunity Letter of Intent Due: Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more NIH-defined population groups who experience health disparities. Appropriate technologies should be effective, affordable, and culturally acceptable.
Letter of Intent Deadline: March 05, 2022
Application Deadline: April 04, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-md-22-004.html
Mar. 08, 2022
NIDDK Funding Opportunity Application Due: Pediatric Obesity Discovery Science Research to Improve Understanding of Risk and Causal Mechanisms for Obesity in Early Life (R01 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to support innovative, discovery research studies to better characterize early-life risk factors and elucidate underlying causal mechanisms through which these risk factors contribute to the development of obesity during infancy and early childhood. Studies should aim to understand biological mechanisms that mediate behavioral and/or metabolic risk for obesity development in young children and how risk may be modified by other contributors such as psychosocial, contextual, and/or environmental factors. This FOA encourages multidisciplinary teams of scientists including, but not limited to those with expertise in basic, translational, clinical, and behavioral research.
Letter of Intent Deadline: February 8, 2022
Application Deadline: March 8, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-025.html
Mar. 08, 2022
NIDDK Funding Opportunity Application Due: Diabetes Research Centers (P30 Clinical Trial Optional)Diabetes Research Centers (P30 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. Diabetes Research Centers support two primary research-related activities: Research Core services and a Pilot and Feasibility (P and F) program. All activities pursued by Diabetes Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in Diabetes Research Center topic areas. The NIDDK Diabetes Research Centers program in 2021 consists of 16 Centers each located at outstanding research institutions with documented programs of excellence in diabetes-related research. General information about the NIDDK Diabetes Research Centers program may be found at www.diabetescenters.org (http://www.diabetescenters.org).
Letter of Intent Deadline: February 8, 2022
Application Deadline: March 8, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-029.html
Mar. 09, 2022
NIDDK Funding Opportunity Application Due: Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel methods, biomaterials and devices for type 1 diabetes (T1D) treatment.
Letter of Intent Deadline: February 09, 2022 and September 7, 2022
Application Deadline: March 9, 2022 and October 7, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-012.html
Mar. 09, 2022
NIDDK Funding Opportunity Application Due: Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies and their integration into open and closed loop hormone replacement systems.
Letter of Intent Due Date: February 9, 2022 and September 7, 2022
Application Due Date: March 9, 2022 and October 7, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-011.html
Mar. 11, 2022
NIH Funding Opportunity Application Due: HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials. The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics. The resulting biomarkers or biomarker signatures may be focused on a single pain condition or on several pain conditions with common underlying pathophysiology. Applications to identify biomarkers or biomarker signatures that predict or monitor a therapeutic response across several related pain conditions should feature Multiple Principal Investigator (MPI)-led teams that represent each of the related pain conditions and associated clinical networks. The MPI-led teams are expected to decide upon a single set of measures or biomarker modalities including, but not limited to a combination of omics, Quantitative Sensory Testing (QST), actigraphy, Electroencephalography (EEG), digital measures, etc.as components of the biosignature for all pain conditions represented in the application.
Studies to be supported by this FOA may include those necessary for the identification and initial biological, analytical, and clinical validation of pain biomarkers or biomarker signatures, and must include human samples and data as the source for candidate biomarkers or signatures identification and development if possible. If not, biomarkers or signatures resulting from identification in animal models must be verified in human samples at the end of the UG3 phase or during the UH3 phase. This initiative aims to deliver therapeutic response prediction and/or monitoring candidate pain biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation appropriate for use in clinical trial design or decision-making in clinical practice.
Letter of Intent Deadline: 30 days prior to application due date
Application Deadline: March 11, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-ns-22-050.html
Mar. 15, 2022
Helmsley T1D Program Funding Opportunity Concept Notes Due: Understanding Relationships Between the Prenatal Development Period and Initiation of Islet Autoimmunity
A goal of the Helmsley Charitable Trust’s (Helmsley) Type 1 Diabetes (T1D) Program is to support the discovery and development of interventions to prevent or delay the development of T1D. However, to identify new potential therapeutic approaches, the predisposing factors and environmental triggers that influence pathogenesis must be better understood.
Concept Notes due: March 15, 2022
Full grant proposal due: June 1, 2022
More Information: https://helmsleytrust.org/request_for_proposal/understanding-relationships-between-prenatal-development-period-and-initiation-of-islet-autoimmunity/
Mar. 15, 2022
Helmsley T1D Program Funding Opportunity Concept Notes Due: Understanding and Therapeutically Emulating Examples Where Individuals Are Naturally Protected From Developing T1D
A goal of the Helmsley Charitable Trust’s (Helmsley) Type 1 Diabetes (T1D) Program is to support the discovery and development of new therapies that will prevent or delay the development of T1D. T1D is a complex autoimmune disease that eliminates insulin-producing beta cells from the pancreas. To identify therapies that have the highest likelihood of preventing or delaying it, the research field needs to understand the disease’s predisposing factors, triggers, and elements that affect its pathogenesis. Understanding these early drivers—and, perhaps more compellingly, what can override these early drivers—could lead to new discoveries into therapy targets or guide new intervention strategies to halt the disease.
Concept Notes due: March 15, 2022
Selected applicants invited to submit grant proposals: April 15, 2022
Full grant proposal due: June 1, 2022
More Information: https://helmsleytrust.org/request_for_proposal/understanding-and-therapeutically-emulating-examples-where-individuals-are-naturally-protected-from-developing-t1d/
Mar. 17, 2022
NIH Funding Opportunity Application Due: Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborations to Improve the AI/ML-Readiness of NIH-Supported Data
This Notice announces the availability of supplements to active grants which are intended to support collaborations that bring together expertise in biomedicine, data management, and artificial intelligence and machine learning (AI/ML) to make NIH-supported data useful and usable for AI/ML analytics. This initiative is aligned with the NIH Strategic Plan for Data Science, which describes actions aimed at modernizing the biomedical research data ecosystem and making data FAIR (Findable, Accessible, Interoperable, and Reusable) with high impact for open science. For the purposes of this Notice, AI/ML is inclusive of machine learning (ML), deep learning (DL), and neural networks (NN).
Application Deadline: March 17, 2022
More Information: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-067.html
Mar. 17, 2022
NIH Funding Opportunity Application Due: HEAL Initiative: Discovery and Functional Evaluation of Human Pain-associated Genes & Cells (U19 Clinical Trial Not Allowed)
The purpose of this funding opportunity announcement is to support research that uses human tissue or cells to generate comprehensive datasets for the discovery and characterization of functional genetic elements, epigenetic signatures, and molecular/cellular pathways that underlie human pain transduction, transmission, and processing. This FOA will support concerted multidisciplinary team science efforts that apply large-scale high-throughput approaches on tissues involved in human pain processing as part of the NIH HEAL Initiative’s Program to Reveal and Evaluate Cells-to-gene Information that Specify Intricacies, Origins, and the Nature of Human Pain (PRECISION Human Pain). U19 Centers will operate as a cooperative network to promote collaboration and coordination of research activities. U19 Centers will also coordinate with the U24 HEAL Initiative: Human Pain-associated Genes & Cells Data Coordination and Integration Center that will curate, harmonize, and integrate datasets generated by this U19 research program.
Letter of Intent Deadline: 30 days prior to the application due date
Application Deadline: March 17, 2022 ; July 7, 2022 ; October 11, 2022 ; March 09, 2023
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-ns-22-018.html
Mar. 22, 2022
NIDDK Funding Opportunity Application Due: NOSI: Notice of Special Interest (NOSI): Support for existing data repositories to align with FAIR and TRUST principles and evaluate usage, utility, and impact
The goal of this Notice of Special Interest (NOSI) is to strengthen NIH-funded biomedical data repositories to better enable data discoverability, interoperability, and reuse by aligning with the FAIR and TRUST principles and using metrics to measure their effectiveness. This NOSI provides an opportunity for existing repositories to increase “FAIR”-ness and “TRUST”-worthiness to improve their usage, utility, and impact throughout the data resource lifecycle.
Application Deadline: March 22, 2022
More Information: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-069.html
Mar. 24, 2022
NIDDK Funding Opportunity Application Due: Analysis, Technology, Leadership, Administration and Science (ATLAS) Center (U24 Clinical Trial Not Allowed)
This Funding Opportunity Announcement intends to support the creation of an Analysis, Technology, Leadership, Administration and Science (ATLAS) Center that has the overarching goal of building the "go-to" open-access resource for the research community of mouse and human renal and genitourinary development and disease. The ATLAS Center will have scientific and administrative responsibilities including: 1) integrating and visualizing disparate datatypes and organs of the renal and genitourinary tract; 2) developing, adopting, or improving state-of-the-art computational tools and approaches to carry out analyses of multi-modal molecular and imaging data; 3) building interactive 2D/3D atlases and molecular maps with FAIR principles (findable, accessible, interoperable, and reusable) to promote data retrieval, exploration, discovery, and analysis by the community; 4) developing, designing, maintaining, and enhancing an open-access, interactive public data and analysis portal; and 5) coordinating internal and external activities of the GenitoUrinary Development Molecular Anatomy Project (GUDMAP) and (Re)Building a Kidney (RBK) consortia, including administration of an opportunity pool to address scientific gaps and opportunities.
Letter of Intent Deadline: February 24, 2022
Application Deadline: March 24, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-034.html
Mar. 24, 2022
NIDDK Funding Opportunity Application Due: Fostering Research With Additional Resources and Development (FORWARD) Urology Centers (P20 Clinical Trial Not Allowed)
The overall goal of the Fostering Research With Additional Resources and Development (FORWARD) Urology Centers program is to foster and expand the benign urologic research community. FORWARD Urology Centers will support a Research Project designed and conducted by a collaborative, multidisciplinary team comprising junior investigators and/or researchers new to the field of benign urologic research. It is expected that the Research Project Team will generate data to support one or more follow-on independent grant applications (e.g., R01s). The Center PD(s)/PI(s) will lead an Administrative (Project Support) Core to provide guidance to the Research Team to help ensure the research aims are met and to aid them in their successful integration into the broader benign urologic research field. To facilitate these goals, the Center will leverage intra- and extra-institutional resources, collaborations and facilities and engage as a member of NIDDK’s CAIRIBU (Collaborating for the Advancement of Interdisciplinary Research in Benign Urology) Program.
Letter of Intent Deadline: February 24, 2022
Application Deadline: March 24, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-032.html
Mar. 31, 2022
NIDDK IIDP Request for Proposals (RFP) Application Due: Affiliated Islet Isolation Centers (IICs)
The purpose of this RFP is to identify and evaluate expert human IICs that can provide the highest quality human isolated islets and related tissues to the Integrated Islet Distribution Program (IIDP) in a dependable, consistent, cost-effective manner. IICs are hereby invited to submit an application in response to this Request for Proposals to become an IIDP IIC. The IIC should be led by an experienced investigator with a solid track record of providing resources and services to the diabetes research community, and should have proficiency in procuring and processing human islets for research use.
Informational Webinar: January 24, 2022 at 11am PST
Letter of Intent Due Date: February 28, 2022
Application Due Date: March 31, 2022
More Information: https://iidp.coh.org/iic_rfp?fbclid=IwAR29OF50c2HYlxJrahwQ-jLWKrEM4VYCaWcTO3rYHCVkJWCKnTD8eKDZV84
Mar. 31, 2022
NIDDK Funding Opportunity Application Due: Elucidating the heterogeneity of impaired awareness of hypoglycemia in Type 1 Diabetes (T1D) - Biostatistics Research Center (U01 Clinical Trial Not Allowed)
This FOA invites applications for a Biostatistics Research Center (BRC) to participate in a clinical consortium to determine the factors that contribute to the heterogeneity in the restoration of impaired awareness of hypoglycemia (IAH) and improved counter-regulatory responses in adult individuals with Type 1 Diabetes (T1D) and impaired awareness of hypoglycemia (IAH). A separate FOA (RFA-DK-21-020) invites Clinical Centers to: 1) determine if the most up-to-date diabetes technology to optimize HbA1c while minimizing hypoglycemia can restore awareness of hypoglycemia and improve counter-regulatory responses in individuals with T1D and IAH; 2) identify the magnitude and duration of time in range (TIR), time spent in hypoglycemia or other CGM metrics that are associated with restoration of awareness of hypoglycemia; and 3) determine the association of current or newly developed self-reported measures of IAH with counter-regulatory responses to elucidate the heterogeneity in restoration of hypoglycemia awareness.
Letter of Intent Deadline: March 01, 2022
Application Deadline: March 31, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-036.html
Mar. 31, 2022
NIDDK Funding Opportunity Application Due: Elucidating the heterogeneity of impaired awareness of hypoglycemia in Type 1 Diabetes (T1D) Clinical Centers (U01 Clinical Trial Required)
The purpose of this FOA is to establish a clinical consortium to determine the factors that contribute to the heterogeneity in the restoration of impaired awareness of hypoglycemia (IAH) and improved counter-regulatory responses in adult individuals with Type 1 Diabetes (T1D). Individuals with IAH are often excluded from clinical trials and this omission contributes greatly to a lack of knowledge regarding the clinical characteristics which determine or predict an individual’s ability to restore hypoglycemic awareness. New technologies such as continuous glucose monitors (CGM) and closed loop systems (i.e. artificial pancreas) have been shown to reduce hypoglycemic events. However, despite a reduction in hypoglycemic events, restoration of hypoglycemia awareness does not occur in all individuals and the effects on improving the counter-regulatory responses are not known.
Letter of Intent Deadline: March 01, 2022
Application Deadline: March 31, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-020.html
Mar. 31, 2022
NIH Funding Opportunity Application Due: Notice of Special Interest (NOSI): Administrative Supplements for Advancing the Ethical Development and Use of AI/ML in Biomedical and Behavioral Sciences
The NIH Office of Data Science Strategy (ODSS) announces the availability of funds for Administrative Supplements to active NIH grants that have a significant Artificial Intelligence and Machine Learning (AI/ML) and/or ethics component. The funds will support collaborations that bring together expertise in ethics, biomedicine, data collection, and AI/ML to advance the understanding, tools, metrics, and practices for the ethical development and use of AI/ML in biomedical and behavioral sciences. This initiative is aligned with the NIH Strategic Plan for Data Science, which describes actions aimed at modernizing the biomedical research data ecosystem. For the purposes of this Notice, AI/ML is inclusive of machine learning (ML), deep learning (DL), and neural network (NN) techniques employed in distributed, federated, local, or cloud environments.
Applicants are strongly encouraged to discuss potential requests with their Institute/Center (IC) Program Official before submitting the supplemental request.
Application Deadline: March 31, 2022
More Information: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-065.html
About
The NIDDK Information Network (dkNET) serves the needs of basic and clinical investigators by providing seamless access to large pools of data and research resources relevant to the mission of The National Institute of Diabetes Digestive and Kidney Diseases (NIDDK). dkNET is hosted at University of California San Diego, and is supported by NIH NIDDK grant 2U24DK097771-09.
Recent News Entries
Contact Us
Email: info_at_ dknet.org
